Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.
Read Article
Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID
Read Article
Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.
Read Article
This is the #1 question I get from new consults: “How did I get arthritis?”
But as aching patients ask this question, they are really thinking these joint complaints must be due to something.
A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype.
Read Article
Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in
Read Article
Patients with systemic lupus erythematosus (SLE) had two to four times higher risk for serious infection requiring hospitalization, a nationwide Swedish study found.
In a multivariate analysis that adjusted for age, sex, region of residence, and education, the hazard ratio for serious
Read Article
Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.
Read Article
A retrospective records review of patients with periodic fever syndromes (PFS) receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.
Read Article
A smartphone-based symptom study of COVID-19 patients has shown that a healthy plant-based diet was associated with lower risk and severity of COVID-19, especially amongst those living in areas with higher socioeconomic deprivation.
Data was collected from 592,571 individuals
Read Article
CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.
This prospective observational study used data from the STOP-JIA trial (Start Time Optimization of
Read Article
Links:
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.
This retrospective analysis assessed treatment patterns among patients newly initiated on biologic
Read Article
This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.
Read Article
Links:
Rheumatology Advisor @RheumAdvisor( View Tweet )
Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.
In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for
Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.
Researchers
Read Article
Links:
Wow! I hope you read part I of yesterday's “Greatest Rheumatologist” article. So many big names and yet, other names and stories that were equally inspirational.
If you read the comments of the part I article you can clearly see several themes emerge.
Read Article
Who is the greatest rheumatologist? What makes for a great rheum? Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring? Rheumatologists are quite opinionated on this subject and very nostalgic about their mentors and leaders. When I’ve
Read Article
Links:
